Trade Lineage Cell Therapeutics, Inc. - LCTX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Lineage Cell Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.16 |
Open* | 1.15 |
1-Year Change* | 1.77% |
Day's Range* | 1.13 - 1.17 |
52 wk Range | 1.02-1.58 |
Average Volume (10 days) | 310.50K |
Average Volume (3 months) | 15.99M |
Market Cap | 241.48M |
P/E Ratio | -100.00K |
Shares Outstanding | 174.99M |
Revenue | 10.52M |
EPS | -0.13 |
Dividend (Yield %) | N/A |
Beta | 1.66 |
Next Earnings Date | Nov 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 1.16 | -0.07 | -5.69% | 1.23 | 1.24 | 1.16 |
Sep 21, 2023 | 1.23 | -0.03 | -2.38% | 1.26 | 1.27 | 1.23 |
Sep 20, 2023 | 1.26 | 0.00 | 0.00% | 1.26 | 1.28 | 1.26 |
Sep 19, 2023 | 1.28 | 0.01 | 0.79% | 1.27 | 1.31 | 1.27 |
Sep 18, 2023 | 1.29 | -0.01 | -0.77% | 1.30 | 1.32 | 1.28 |
Sep 15, 2023 | 1.30 | 0.03 | 2.36% | 1.27 | 1.33 | 1.26 |
Sep 14, 2023 | 1.28 | 0.01 | 0.79% | 1.27 | 1.30 | 1.26 |
Sep 13, 2023 | 1.28 | -0.01 | -0.78% | 1.29 | 1.31 | 1.28 |
Sep 12, 2023 | 1.30 | 0.01 | 0.78% | 1.29 | 1.32 | 1.28 |
Sep 11, 2023 | 1.29 | 0.01 | 0.78% | 1.28 | 1.34 | 1.28 |
Sep 8, 2023 | 1.33 | 0.00 | 0.00% | 1.33 | 1.37 | 1.33 |
Sep 7, 2023 | 1.35 | 0.04 | 3.05% | 1.31 | 1.36 | 1.31 |
Sep 6, 2023 | 1.33 | -0.03 | -2.21% | 1.36 | 1.36 | 1.32 |
Sep 5, 2023 | 1.34 | 0.02 | 1.52% | 1.32 | 1.38 | 1.31 |
Sep 1, 2023 | 1.32 | 0.00 | 0.00% | 1.32 | 1.34 | 1.30 |
Aug 31, 2023 | 1.29 | -0.04 | -3.01% | 1.33 | 1.35 | 1.29 |
Aug 30, 2023 | 1.32 | -0.01 | -0.75% | 1.33 | 1.39 | 1.32 |
Aug 29, 2023 | 1.35 | 0.04 | 3.05% | 1.31 | 1.37 | 1.30 |
Aug 28, 2023 | 1.33 | 0.01 | 0.76% | 1.32 | 1.35 | 1.32 |
Aug 25, 2023 | 1.32 | -0.02 | -1.49% | 1.34 | 1.34 | 1.30 |
Lineage Cell Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, November 8, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Lineage Cell Therapeutics Inc Earnings Release Q3 2023 Lineage Cell Therapeutics Inc Earnings ReleaseForecast -Previous - |
Thursday, March 7, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Lineage Cell Therapeutics Inc Earnings Release Q4 2023 Lineage Cell Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 14.703 | 4.341 | 1.826 | 3.515 | 4.988 |
Revenue | 14.703 | 4.341 | 1.826 | 3.515 | 4.988 |
Cost of Revenue, Total | 0.728 | 1.426 | 0.385 | 0.412 | 0.302 |
Gross Profit | 13.975 | 2.915 | 1.441 | 3.103 | 4.686 |
Total Operating Expense | 37.223 | 53.029 | 28.273 | 42.391 | -31.728 |
Selling/General/Admin. Expenses, Total | 22.508 | 18.212 | 15.571 | 24.031 | 24.726 |
Research & Development | 13.887 | 33.714 | 11.117 | 15.948 | 18.755 |
Unusual Expense (Income) | 0 | -0.523 | 0 | -77.711 | |
Operating Income | -22.52 | -48.688 | -26.447 | -38.876 | 36.716 |
Interest Income (Expense), Net Non-Operating | -1.365 | 3.727 | 1.817 | 16.499 | -82.531 |
Other, Net | -1.927 | 1.691 | 2.706 | 3.143 | -1.315 |
Net Income Before Taxes | -25.812 | -43.27 | -21.924 | -19.234 | -47.13 |
Net Income After Taxes | -26.353 | -43.27 | -20.685 | -11.827 | -46.784 |
Minority Interest | 0.08 | 0.251 | 0.036 | 0.118 | 0.794 |
Net Income Before Extra. Items | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Net Income | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Income Available to Common Incl. Extra. Items | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Dilution Adjustment | |||||
Diluted Net Income | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Diluted Weighted Average Shares | 169.792 | 164.502 | 150.044 | 145.533 | 126.903 |
Diluted EPS Excluding Extraordinary Items | -0.15474 | -0.26151 | -0.13762 | -0.08046 | -0.3624 |
Diluted Normalized EPS | -0.15474 | -0.26469 | -0.13762 | -0.08046 | -0.75823 |
Depreciation / Amortization | 0.1 | 0.2 | 1.2 | 2 | 2.2 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 3.225 | 2.386 | 1.915 | 2.998 | 4.553 |
Revenue | 3.225 | 2.386 | 1.915 | 2.998 | 4.553 |
Cost of Revenue, Total | 0.127 | 0.119 | 0.102 | 0.235 | 0.215 |
Gross Profit | 3.098 | 2.267 | 1.813 | 2.763 | 4.338 |
Total Operating Expense | 8.249 | 9.028 | 8.554 | 8.249 | 8.787 |
Selling/General/Admin. Expenses, Total | 4.249 | 4.724 | 4.348 | 4.422 | 5.27 |
Research & Development | 3.873 | 4.185 | 4.104 | 3.592 | 3.302 |
Depreciation / Amortization | |||||
Operating Income | -5.024 | -6.642 | -6.639 | -5.251 | -4.234 |
Interest Income (Expense), Net Non-Operating | 0.232 | 0.45 | -0.123 | 0.151 | -0.658 |
Other, Net | -0.411 | -0.015 | 0.4 | -0.475 | -1.89 |
Net Income Before Taxes | -5.203 | -6.207 | -6.362 | -5.575 | -6.782 |
Net Income After Taxes | -5.203 | -4.404 | -6.362 | -6.116 | -6.782 |
Minority Interest | -0.026 | 0.032 | 0.008 | 0.047 | 0.019 |
Net Income Before Extra. Items | -5.229 | -4.372 | -6.354 | -6.069 | -6.763 |
Net Income | -5.229 | -4.372 | -6.354 | -6.069 | -6.763 |
Income Available to Common Excl. Extra. Items | -5.229 | -4.372 | -6.354 | -6.069 | -6.763 |
Income Available to Common Incl. Extra. Items | -5.229 | -4.372 | -6.354 | -6.069 | -6.763 |
Diluted Net Income | -5.229 | -4.372 | -6.354 | -6.069 | -6.763 |
Diluted Weighted Average Shares | 170.592 | 170.127 | 170.002 | 169.786 | 169.731 |
Diluted EPS Excluding Extraordinary Items | -0.03065 | -0.0257 | -0.03738 | -0.03574 | -0.03985 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.03065 | -0.0257 | -0.03738 | -0.03574 | -0.03985 |
Unusual Expense (Income) | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 60 | 111.549 | 43.999 | 57.519 | 36.358 |
Cash and Short Term Investments | 57.875 | 58.358 | 41.562 | 30.716 | 30.741 |
Cash & Equivalents | 11.355 | 55.742 | 32.585 | 9.497 | 23.587 |
Short Term Investments | 46.52 | 2.616 | 8.977 | 21.219 | 7.154 |
Total Receivables, Net | 0.297 | 50.84 | 0.004 | 23.94 | 3.719 |
Accounts Receivable - Trade, Net | 0.297 | 50.84 | 0.004 | 0.044 | 0.891 |
Prepaid Expenses | 1.828 | 2.351 | 2.433 | 2.863 | 1.898 |
Total Assets | 123.664 | 174.545 | 107.949 | 125.478 | 101.66 |
Property/Plant/Equipment, Total - Net | 5.673 | 4.872 | 5.63 | 8.175 | 5.835 |
Property/Plant/Equipment, Total - Gross | 11.523 | 10.174 | 9.945 | 12.766 | 9.02 |
Accumulated Depreciation, Total | -5.85 | -5.302 | -4.315 | -4.591 | -3.185 |
Intangibles, Net | 46.692 | 46.822 | 47.032 | 48.248 | 3.125 |
Long Term Investments | 0 | 33.733 | |||
Other Long Term Assets, Total | 0.627 | 0.63 | 0.616 | 0.864 | 0.505 |
Total Current Liabilities | 18.981 | 47.116 | 7.769 | 6.494 | 6.812 |
Accounts Payable | 2.393 | 3.543 | 2.611 | 2.427 | 2.359 |
Accrued Expenses | 7.131 | 25.049 | 4.416 | 3.985 | 4.332 |
Notes Payable/Short Term Debt | 0 | 0 | 0.523 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.036 | 0.03 | 0.016 | 0.033 | 0.07 |
Other Current Liabilities, Total | 9.421 | 18.494 | 0.203 | 0.049 | 0.051 |
Total Liabilities | 50.325 | 82.324 | 11.75 | 12.519 | 7.82 |
Total Long Term Debt | 0.084 | 0.03 | 0.026 | 0.077 | 1.958 |
Long Term Debt | 0 | ||||
Capital Lease Obligations | 0.084 | 0.03 | 0.026 | 0.077 | 1.958 |
Minority Interest | -1.403 | -1.323 | -1.072 | -1.712 | -1.594 |
Other Liabilities, Total | 30.587 | 34.425 | 2.951 | 4.345 | 0.644 |
Total Equity | 73.339 | 92.221 | 96.199 | 112.959 | 93.84 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 440.28 | 434.529 | 393.944 | 387.062 | 354.27 |
Retained Earnings (Accumulated Deficit) | -363.37 | -337.097 | -294.078 | -273.422 | -261.856 |
Treasury Stock - Common | |||||
Other Equity, Total | -3.571 | -5.211 | -3.667 | -0.681 | 1.426 |
Total Liabilities & Shareholders’ Equity | 123.664 | 174.545 | 107.949 | 125.478 | 101.66 |
Total Common Shares Outstanding | 170.093 | 169.477 | 153.096 | 149.804 | 127.136 |
Note Receivable - Long Term | 0 | 22.104 | |||
Goodwill, Net | 10.672 | 10.672 | 10.672 | 10.672 | |
Deferred Income Tax | 2.076 | 2.076 | 2.076 | 3.315 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 49.655 | 60 | 68.509 | 74.026 | 81.872 |
Cash and Short Term Investments | 46.814 | 57.875 | 66.355 | 72.03 | 79.944 |
Cash & Equivalents | 15.451 | 11.355 | 24.752 | 70.857 | 78.062 |
Short Term Investments | 31.363 | 46.52 | 41.603 | 1.173 | 1.882 |
Total Receivables, Net | 0.203 | 0.297 | 0.434 | 0.707 | 0.515 |
Accounts Receivable - Trade, Net | 0.203 | 0.297 | 0.434 | 0.707 | 0.515 |
Prepaid Expenses | 2.638 | 1.828 | 1.72 | 1.289 | 1.413 |
Total Assets | 113.205 | 123.664 | 131.148 | 135.922 | 144.52 |
Property/Plant/Equipment, Total - Net | 5.584 | 5.673 | 4.652 | 3.869 | 4.548 |
Property/Plant/Equipment, Total - Gross | 11.694 | 11.523 | 10.464 | 9.414 | 10.135 |
Accumulated Depreciation, Total | -6.11 | -5.85 | -5.812 | -5.545 | -5.587 |
Goodwill, Net | 10.672 | 10.672 | 10.672 | 10.672 | 10.672 |
Intangibles, Net | 46.659 | 46.692 | 46.724 | 46.757 | 46.789 |
Other Long Term Assets, Total | 0.635 | 0.627 | 0.591 | 0.598 | 0.639 |
Total Current Liabilities | 17.225 | 18.981 | 22.739 | 25.091 | 24.593 |
Accounts Payable | 3.001 | 2.393 | 2.865 | 2.589 | 2.956 |
Accrued Expenses | 3.126 | 7.131 | 7.46 | 6.678 | 6.642 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.051 | 0.036 | 0.025 | 0.029 | 0.031 |
Other Current Liabilities, Total | 11.047 | 9.421 | 12.389 | 15.795 | 14.964 |
Total Liabilities | 42.755 | 50.325 | 52.2 | 53.075 | 57.973 |
Total Long Term Debt | 0.133 | 0.084 | 0.016 | 0.019 | 0.026 |
Capital Lease Obligations | 0.133 | 0.084 | 0.016 | 0.019 | 0.026 |
Deferred Income Tax | 0.273 | 2.076 | 2.076 | 2.076 | 2.076 |
Minority Interest | -1.435 | -1.403 | -1.395 | -1.348 | -1.329 |
Other Liabilities, Total | 26.559 | 30.587 | 28.764 | 27.237 | 32.607 |
Total Equity | 70.45 | 73.339 | 78.948 | 82.847 | 86.547 |
Common Stock | 441.299 | 440.28 | 439.148 | 437.151 | 435.818 |
Retained Earnings (Accumulated Deficit) | -367.742 | -363.37 | -357.016 | -350.947 | -344.184 |
Other Equity, Total | -3.107 | -3.571 | -3.184 | -3.357 | -5.087 |
Total Liabilities & Shareholders’ Equity | 113.205 | 123.664 | 131.148 | 135.922 | 144.52 |
Total Common Shares Outstanding | 170.174 | 170.093 | 169.886 | 169.748 | 169.727 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Cash From Operating Activities | 1.059 | -23.561 | -19.753 | -31.947 | -30.882 |
Cash From Operating Activities | 0.582 | 0.663 | 0.895 | 1.131 | 1.081 |
Amortization | 0.145 | 0.21 | 1.216 | 1.998 | 2.192 |
Deferred Taxes | |||||
Non-Cash Items | 7.901 | -2.511 | -2.516 | -21.464 | 11.197 |
Cash Interest Paid | 0.013 | 0.013 | 0.02 | 0.028 | 0.155 |
Changes in Working Capital | 18.704 | 21.096 | 1.301 | -1.903 | 0.638 |
Cash From Investing Activities | -46.159 | 9.745 | 13.038 | 16.957 | 11.816 |
Capital Expenditures | -0.413 | -0.354 | -0.064 | -0.44 | -3.287 |
Other Investing Cash Flow Items, Total | -45.746 | 10.099 | 13.102 | 17.397 | 15.103 |
Cash From Financing Activities | 1.632 | 36.93 | 29.865 | 0.617 | 5.774 |
Financing Cash Flow Items | -0.123 | -1.155 | -0.383 | 0.654 | 0.161 |
Issuance (Retirement) of Stock, Net | 1.787 | 38.105 | 5.127 | 0.063 | 5.962 |
Issuance (Retirement) of Debt, Net | -0.032 | -0.02 | 25.121 | -0.1 | -0.349 |
Foreign Exchange Effects | -0.873 | -0.02 | -0.063 | 0.07 | 0.006 |
Net Change in Cash | -44.341 | 23.094 | 23.087 | -14.303 | -13.286 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.372 | -26.273 | -19.919 | -13.85 | -7.087 |
Cash From Operating Activities | -11.242 | 1.059 | 9.362 | 14.842 | 21.904 |
Cash From Operating Activities | 0.138 | 0.582 | 0.441 | 0.296 | 0.15 |
Amortization | 0.033 | 0.145 | 0.113 | 0.065 | 0.032 |
Non-Cash Items | 1.098 | 7.901 | 7.168 | 5.861 | 1.685 |
Cash Interest Paid | 0.002 | 0.013 | 0.013 | 0.009 | 0.005 |
Changes in Working Capital | -8.139 | 18.704 | 21.559 | 22.47 | 27.124 |
Cash From Investing Activities | 15.426 | -46.159 | -41.057 | -0.143 | -0.046 |
Capital Expenditures | -0.188 | -0.413 | -0.429 | -0.143 | -0.046 |
Other Investing Cash Flow Items, Total | 15.614 | -45.746 | -40.628 | 0 | 0 |
Cash From Financing Activities | 0.001 | 1.632 | 1.51 | 0.546 | 0.513 |
Financing Cash Flow Items | -0.037 | -0.123 | -0.112 | -0.074 | -0.008 |
Issuance (Retirement) of Stock, Net | 0.051 | 1.787 | 1.645 | 0.635 | 0.529 |
Foreign Exchange Effects | -0.1 | -0.873 | -0.795 | -0.161 | -0.042 |
Net Change in Cash | 4.085 | -44.341 | -30.98 | 15.084 | 22.329 |
Deferred Taxes | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | -0.013 | -0.032 | -0.023 | -0.015 | -0.008 |
Cash Taxes Paid | 1.803 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lineage Cell Therapeutics, Inc. Company profile
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company''s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.Industry: | Biotechnology & Medical Research (NEC) |
2173 Salk Ave Ste 200
CARLSBAD
CALIFORNIA 92008-7354
US
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com